awmsg logo



fluticasone furoate/vilanterol (as trifenatate) (Relvar® Ellipta®)


Reference No. 1534

Publication date:
27/05/2014


Appraisal information

fluticasone furoate/vilanterol (as trifenatate) (Relvar® Ellipta®) 92 micrograms/22 micrograms inhalation powder


Company: GlaxoSmithKline
BNF category: Respiratory system
NMG meeting date: 09/04/2014
AWMSG meeting date: 07/05/2014
   
   
Submission Type: Full Submission
Status: Recommended
Advice No: 1014
Ministerial ratification: 23/05/2014

Current Progress


Submission
received
NMG
meeting
AWMSG
meeting
Ministerial
Ratification

AWMSG advice

Fluticasone furoate/vilanterol (as trifenatate) (Relvar® Ellipta®) is recommended as an option for use within NHS Wales for the symptomatic treatment of adults with chronic obstructive pulmonary disease with a FEV1< 70% predicted normal (post-bronchodilator) with an exacerbation history despite regular bronchodilator therapy.
Final Appraisal Recommendation (FAR)
Download
AWMSG Secretariat Appraisal Report (ASAR)
Download
Clinical Expert (CE) Summary
Download